Happy holidays!

With today's issue, we're concluding another year's coverage of the pharma industry. FiercePharma and its sister publications will be taking a publishing holiday until January 5th, when we'll be back with our annual forecast for the industry, including a look at FiercePharma's most popular stories of 2008. Enjoy the holidays and look for us in the New Year! - Maureen

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.